Awakn Life Sciences (TSE:AWKN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Awakn Life Sciences has partnered with the University of Nottingham to conduct preclinical trials on a new chemical entity aimed at enhancing mental health treatments. The study, led by Dr. Madeleine King, focuses on the potential of aminoindane to improve social cognition and behaviors, particularly for PTSD. This collaboration marks a significant step in Awakn’s mission to develop innovative therapies for mental health disorders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.